Drug Trial Radar · NCT05223920
An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)
Last checked: Nov 19, 2026Latest source record: Sep 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
81
Actual
Start
Dec 15, 2021
Primary completion
Aug 22, 2024
Study completion Aug 22, 2024
Sponsor
- Lead sponsor
- Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)Industry
- Sponsor type
- Industry
- First posted
- Feb 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open-label extension study to assess the long-term safety and efficacy of bomedemstat administered orally once daily in participants with a Myeloproliferative Neoplasm (MPN) who participated in a prior bomedemstat study such as, but not limited to, IMG-7289-CTP-102/MK-3543-002 (NCT03136185) and IMG-7289-CTP-201/MK-3543-003 (NCT04254978) (referred to hereafter as 'feeder studies').
Conditions
- Thrombocythemia, Essential
- Primary Myelofibrosis
Interventions
BomedemstatDrug
Capsule (oral)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Experience an Adverse Event (AE)Time frame: Up to ~32 months
- Percentage of Participants Who Discontinue Study Intervention Due to an AETime frame: Up to ~32 months
- Mean Spleen Volume Reduction Based on Spleen Volume Measured by MRI in Participants With MF.Time frame: Baseline and Days 169, 339, 509, 679, 849 and 924
- Percentage of Participants With ET Who Achieve a Reduction of Platelet Counts to <= 400 K/uL (400 x 10^9/L) in the Absence of New Thromboembolic EventsTime frame: Baseline and Days 29, 57, 85, 113, 141, 169, 198, 226, 254, 282, 310, 338, 367, 395, 423, 451, 479, 507, 536, 564, 592, 620, and 648
Locations
19 sites in 7 countries. Site status is shown where the registry gives one.
University of Miami Leonard M. Miller
Miami, Florida
University of Michigan
Ann Arbor, Michigan
Cleveland Clinic Foundation
Cleveland, Ohio
UMPC Hillman Cancer Center
Pittsburgh, Pennsylvania
Fred Hutchinson Cancer Center
Seattle, Washington
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Royal North Shore Hospital
Saint Leonards, New South Wales, Australia
Gold Coast Hospital and Health Service
Southport, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Universittsklinikum Essen
Essen, Germany
Queen Mary Hospital
Hong Kong, Hong Kong
Azienda Ospedaliera SS. Antonio
Alessandria, Italy
Azienda Ospedaliero-Universitaria Careggi - S.O.D. Ematologia (CRIMM)
Florence, Italy
Azienda Ospedaliero Universitaria di Bologna
Pavia, Italy
Ospedale di Circolo-a Fondazione Macchi
Varese, VA, Italy
Middlemore Clinical Trials
Papatoetoe, Aukland, New Zealand
Waitemata District Health Board
Takapuna, Aukland, New Zealand
University College London Hospitals NHS Foundation Trust
London, United Kingdom
Guy's and Saint Thomas' NHS Foundation Trus
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.